Evidence map›Paper›PMID 30798483›Full record

ArticleJournal of robotic surgery2020

Robotic hepatectomy for benign and malignant liver tumors.

Iswanto Sucandy, Sydni Schlosser, Timothy Bourdeau, Janelle Spence, Abdelrahman Attili, Sharona Ross, Alexander Rosemurgy

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of robotic surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Robot-assisted radical cholecystectomy for gallbladder cancer: A review.Journal of clinical and translational research · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Iswanto SucandyDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA. iswanto.sucandy@ahss.org.ORCID http://orcid.org/0000-0003-2167-3215
Sydni SchlosserDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.
Timothy BourdeauDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.
Janelle SpenceDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.
Abdelrahman AttiliDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.
Sharona RossDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.
Alexander RosemurgyDigestive Disease Institute, Florida Hospital Tampa, 3000 Medical Park Dr, Suite #500, Tampa, FL, 33613, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Minimally invasive hepatectomy for benign and malignant liver lesions has gained popularity in the past decade due to improved perioperative outcomes when compared to conventional 'open' technique. We aim to investigate our initial experience of robotic hepatectomy undertaken in our hepatobiliary program. All patients undergoing robotic hepatectomy between 2013 and 2018 were prospectively followed. Data are presented as median (mean ± SD). A total of 80 patients underwent robotic hepatectomy within the study period. 60% of the patients were women, age of 63 (62.4 ± 14.1), body mass index of 28 (29.6 ± 9.4), ASA class of 2.5 (2.5 ± 0.6), and MELD score of 7 (8.2 ± 2.8). Size of resected lesion was 3.9 (4.6 ± 3) cm. Indications for resection were metastatic lesions (30%), hepatocellular carcinoma (28%), cholangiocarcinoma (7%), gallbladder cancer (5%), neuroendocrine tumors (4%), and benign lesions (26%). Formal hepatectomy (right or left) was performed in 30% of the patients. Operative time was 233 (267.2 ± 109.6) minutes, and estimated blood loss was 150 (265.7 ± 319.9) ml. Length of hospital stay was 3 (5.0 ± 4.6) days. One patient was converted to 'open' approach. 10 patients experienced postoperative complications. Readmissions within 30 days of hospital discharge were seen in eight patients. Our data support that robotic hepatectomy is safe and feasible, with favorable short-term outcomes and low conversion rate. Robotic technology extends the application of minimally invasive techniques in the field of hepatobiliary surgery.

Indexed as

AgedBlood Loss, SurgicalCarcinoma, HepatocellularCholangiocarcinomaFemaleHepatectomyHumansLength of StayLiver NeoplasmsMaleMiddle AgedOperative TimePregnancyPrognosisRobotic Surgical ProceduresBenign liver tumorsMalignant liver tumorsRobotic hepatectomy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.